Skip to content

Clinical study for pelvic radiotherapy compared with prophylactic extended field radiotherapy in pelvic lymph node positive cervical cancer

Clinical study for pelvic radiotherapy compared with prophylactic extended field radiotherapy in pelvic lymph node positive cervical cancer

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000029471
Enrollment
Unknown
Registered
2020-02-02
Start date
2020-03-01
Completion date
Unknown
Last updated
2020-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical Cancer

Interventions

Pelvic radiotherapy group:Concurrent chemoradiotherapy
Extended field radiotherapy:Concurrent chemoradiotherapy

Sponsors

Guizhou Cancer Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1. Patients were completely voluntary and autonomous, signed research informed consent 30 days before enrollment. 2. Pathologically confirmed positive pelvic lymph nodes (except total lymph node metastasis) Cervical cancer. 3. Aged 18 to 70 years; 4. Abdominal CT, MRI, or PET / CT found no retroperitoneal metastatic lymph nodes; 5. No evidence of distant metastasis; 6. ECOG score 0-2 or KPS score >=70; 7. The total blood cell count and basal metabolic index within 14 days before enrollment must meet the following requirements: NEUT >=1.5 * 10^9/L, HGB >=80 g/L, and blood creatinine <1.5 mg/dl; AST and ALT are within 2 times the upper limit of normal; 8. Assessments and examinations required before treatment must be completed before enrollment.

Exclusion criteria

Exclusion criteria: (1) There is metastasis to the total lymph nodes of the salamander; (2) Vaginal involvement is up to 1/3; (3) Involvement of bladder and rectal mucosa; (4) received cervical cancer radiotherapy or chemotherapy before treatment; (5) History of malignant tumors; (6) Previous medical history of abdominal or pelvic radiotherapy; (7) Women during pregnancy or lactation; (8) History of active inflammatory bowel disease, or severe gastric and duodenal ulcers; (9) With active infection and fever; (10) Those who are unable to tolerate concurrent chemoradiotherapy; (11) It is expected that internal radiation cannot be accepted; (12) History of severe lung or heart disease; (13) Circumstances in which other examiners determined from the enrollment study to be well-founded as failing: There were potential cases of non-compliance with the clinical protocol.

Design outcomes

Primary

MeasureTime frame
Curative effect;

Contacts

Public ContactFenghu Li

Affiliated Hospital of Guizhou Medical University/ Guizhou Cancer Hospital

769654418@qq.com+86 0851 86513080

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026